Medicare may begin to cover renal denervation with Medtronic’s Symplicity device by October, which could drive coverage among ...

The stock's fall snapped a two-day winning streak.

Medtronic (MDT) concluded the recent trading session at $85.40, signifying a +0.18% move from its prior day's close.

Medtronic is picking up steam with recent product launches, and its balance sheet is a fortress. Read more about MDT stock ...

Medtronic will be the exclusive U.S. distributor of Contego Medical’s portfolio, which includes a carotid stent system and ...

Brookstone Capital Management lifted its stake in shares of Medtronic plc (NYSE:MDT – Free Report) by 11.4% during the 4th quarter, according to the company in its most recent filing with the ...

Medtronic says CMS is opening a national coverage analysis on renal denervation (RDN) procedures for patients with ...

Medtronic (NYSE: MDT) announced today that it received CE mark approval for its BrainSense adaptive deep brain stimulation ...

For not just years but decades, Medtronic (NYSE: MDT) has proven to be a reliable dividend growth stock to own. The medical ...

While deep-brain stimulation therapy has been available for people with Parkinson’s disease for decades, Medtronic has now ...

Medtronic offers solid income potential with a 3.5% dividend yield. Read why MDT stock’s forward P/E ratio signals possible ...

Salem Investment Counselors Inc. trimmed its position in Medtronic plc (NYSE:MDT – Free Report) by 17.1% in the fourth ...